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Activation of Torpedo presynaptic muscarinic acetylcholine (ACh) receptors with the agonist oxatremarine 
(20 ,&f) results in the inhibition of CaZ+ -dependent release of endogenous ACh from Torpedo 
synaptosomes. This effect is reversed by the muscarinic antagonist atropine (I &I) which, by itself, has 
no effect. In contrasi, under the same conditions the amount of newly synthesized radiolabeled [‘WfACh 
reteased is not affected by muscarinic ligands. These findings suggest that presynaptic muscarinic 
inhibition in the Torpedo is due to interference with the mobilization of ACh from a storage pool. 
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11 INTRODUCTION 
Acetylcholine (ACh) release from Tarpedcr 
cholinergic nerve terminals is regulated by 
presynaptic muscarinic ACh receptors (AChR) 
[i-3}, which inhibit release by interfering with the 
coupling, within the nerve terminal, between the 
increased cytoplasmic Ca2’ and ACh secretion 
[2,4]. The nature of the intraterminal event that is 
blocked by muscarinic agonists is not known. 
In the nerve terminal ACh is present in several 
compartments which are defined according to their 
subcellular localization (e.g., vesicular and 
cytoplasmic ACh) and metabolic state. In the 
Torpedo [3] and numerous other cholinergic 
preparations [5-S] newly formed ACh is released 
preferentially following stimulation of the nerve 
terminal, implying that the newly synthesized and 
endogenous ACh are compartmentalized within 
the nerve terminal. 
the synaptosomal release of newly synthesized and 
of endogenous ACh. The experimental approach 
was to radiolabel the newly formed ACh and then 
measure the effect of muscarinic ligands on the 
release of the endogenous ACh, which was assayed 
chemically, and af the radiolabeled newly syn- 
thesized ACh. The results obtained indicate that 
under the conditions employed, muscarinic 
agonists inhibit the release of endogenous ACh but 
have no detectable ffect on the amount of newly 
synthesized ACh released. 
2. EXPERIMENTAL 
We here examined the possibility that 
muscarinic activation has a differential effect on 
* To whom correspondence should be addressed 
Torpedo csceflafa were caught live off the coast 
of Tel-Aviv during the autumn and winter and 
were maintained in sea water aquaria up to 3 
months prior to use. Cholinergic synaptosomes 
{fraction az) were purified from the homogenate of 
fresh Tor~do electric organs by differential and 
density gradient centrifugation as in [9]. The 
synaptosomes (1.2-2.4 mg protein/ml) were 
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diluted 2-fold with modified Torpedo Krebs 
Ringer (TKR) (250 mM NaCl; 4.8 mM KCl; 2.4 
mM MgCl2; 0.1 mM EGTA; 10 mM glucose; 260 
mM sucrose; 20 mM HEPES, pH 7.2) which con- 
tained 10 pM choline, 10 /IM acetate and either 
[3H]choline (1 &i/ml) or [3H]acetate (1 ,&i/ml). 
The synaptosomes were then incubated at 25°C for 
2 h and subsequently transferred to 4°C for up to 
3 h prior to use. Control experiments revealed that 
the profiles of ACh and 13H]ACh release were not 
affected by storage of the synaptosomes at 4°C for 
up to 3 h. Protein was determined as in [lo]. 
2.2. measurement of syna~tosomal release and of 
newly synthesized rad~oia~e~ed acety~cho~i~e 
Release experiments were performed in a con- 
tinuous flow apparatus [ll] in which the synap- 
tosomes (0.3-0.7 mg protein) were loaded onto a 
GF/C filter (Whatman) mounted on a holder (25 
mm diameter; 0.5 ml volume) and washed with 20 
ml of modified TKR. A baseline was then 
established by flowing 3 ml of modified TKR (at a 
flow rate of 1 ml/min), which were collected as 0.5 
ml fractions. Release was induced by flowing 3 ml 
of a Kf buffer which contained 2 mM Ca’” follow- 
ed by 3 ml of modified TKR. The K+ buffer was 
similar to the modified TKR, except that it con- 
tained 125 mM KC1 and 130 mM NaCl. When the 
effect of muscarinic ligands was examined, they 
were added 2 min (atropine) and 1 min (ox- 
otremorine) prior to K+ depolarization. 
The levels of endogenous ACh release were 
measured by the ~hemilumines~en~e m thod in 
[12], which is based on conversion of the choline, 
produced by hydrolysis of the released ACh, to be- 
taine and Hz02 and detection of the latter by the 
luminol peroxidase system. Release of newly syn- 
thesized radiolabeled ACh was monitored by li- 
quid scintillation spectrometry. In several ex- 
periments, the synaptosomal acetylcholinesterase 
(AChE) was inhibited with phospholine iodide 
(100 PM for 30 min). The amount of endogenous 
ACh iiberated under these conditions was analyzed 
by monitoring the increase in the choline content 
of the eluted fractions following the addition of ex- 
ogenous active AChE [12]. The amount of 
[3H]acetate-ACh released was determined by ex- 
amining the effect of the added AChE on the ex- 
traction of the eluted radioactivity from an acidic 
buffer to an organic phase [13]. 
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3. RESULTS 
Incubation of 7’orpedo synaptosomes with 
[3HJcholine or 13H]acetate resulted in their ac- 
cumulation within the nerve terminal (0.7 _+ 0.08 
nmol [3H]choline and 1.2 at 0.14 nmol 
[3H]acetate/mg protein following a 2-h incuba- 
tion; N = 6) and, as was previously shown, in their 
conversion to f3H]ACh (11,14]. K+ depolarization 
in the presence of Ca2+ of f3H]choline-prelabeled 
synaptosomes resulted in liberation of choline (13 
+ 7 nmol/mg protein; N = 18) and [3H]choline (45 
+ 15 pmol/mg protein, N = 18) (fig. 1). K+ 
depolarization in the absence of Ca’+ and with 
Cat+ by itself had no effect. Similar results were 
obtained with [‘HIacetate-labeled synaptosomes 
(22 + 11 pmol [3H]acetate released/mg protein; N 
= 7). Pretreatment of [3H]acetate-labeled prepara- 
tion with phospholine iodide (an inhibitor of 
AChE) resulted in the recovery of most of the 
released choline (> 75%) and (3H]acetate (> 9OVo) 
moeities as ACh and 13H]acetate-ACh, respective- 
ly. The amount of radioactive material released 
was calculated based on the specific activity of the 
Fig. 1. Ca*+-dependent K’-depolarization-mediated 
release of endogenous synaptosomal choline (0) and 
[3H]choline (a). Prelabeled Torpedo synaptosomes (0.7 
mg protein) were loaded onto a continuous flow 
apparatus, stimulated by KC1 (125 mM) in the presence 
of Ca2+ (2 mM), and the choline and [3H]choline 
released were collected and assayed as described in 
section 2. 
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externally added precursors and therefore cor- 
responds only to the newly formed [3H]ACh syn- 
thesized from these precursors during the prein- 
cubation, and not to the newly synthesized ACh 
which was formed from endogenous precursors. 
The contribution of the newly formed [3H]ACh to 
that of the total ACh release is 0.35 + 0.2% (AJ = 
18) (note different scales in fig. l), thus enabling a 
separate and parallel investigation of the effects of 
modulators of release on these ACh compart- 
ments. 
Activation of the presynaptic muscarinic AChR 
with the agonist oxotremorine (20 PM) caused a 
marked diminution in the amount of endogenous 
ACh released (54 t 13% of control; N = 5). This 
effect was completely reversed by the muscarinic 
antagonist atropine (1 FM) which, by itself, had no 
effect (fig. 2A). It should be noted that the potency 
of oxotremorine varies throughout the year so that 
during the winter 10pM caused maxima1 inhibition 
(> 90%) of release whereas during the spring 50 
FM of oxotremorine had only a partial effect. The 
reason for this seasonal variation is not yet known. 
In contrast to the above findings, oxotremorine 
(up to lOOaM) and atropine (up to lOpM), under 
the same conditions, had no detectable effect on 
the amount of newly synthesized [3HJACh released 
(fig. 2B). The amount of f3H]ACh released in the 
presence of oxotremorine (20pM) and a&opine (1 
PM) was, respectively 90 + 7% (IV = 5) and 100 
+ 10% (N = 3) of control.. 
4. DISCUSSION 
We here report that activation of presynaptic 
muscarinic AChR inhibits the release, from 
Torpedo synaptosomes, of endogenous ACh but 
not of newly synthesized 13H]ACh. There seems to 
be a small delay in the release of 13H]ACh, which 
is caused by oxotremorine and reversed by 
atropine (fig. 2B). Further studies with finer 
kinetic resolution are required in order to delineate 
this possibility. 
Here, the newly formed [3H]ACh was synthesiz- 
ed within 2 h after the introduction of the labeled 
precursors. In [3] it was shown that incubation of 
electric organ tissue blocks with [3H]precursor for 
6 h at 25”C, followed by an overnight incubation 
at 7°C without precursors results in [3H]ACh 
Fig. 2. The effect of oxotremorine and of exotremorine 
plus atropine on Ca*+-dependent Kf-depolarization- 
mediated release of endogenous (A), and radiolabelled 
(B) synaptosomal choline. The experiment was 
performed as in fig. 1, except that the amount of 
synaptosomes used was 0.3 mg protein. (0~0, A) 
K’-depolarization in the presence of Ca’+, Ca2’ and 
oxotremorine (20 yM), and Ca’+ with oxotremorine (20 
PM) and atropine (1 FM), respectively. 
release which is inhibited by oxotremorine. This 
difference may be due to the synaptosomal 
preparation and assaying conditions. Alternative- 
ly, it may suggest hat, in Torpedo, the time of 
transfer of the newly synthesized [3H]ACh to the 
muscarinic-sensitive pool is greater than 2 h and 
less than 18 h. 
It is not yet known how the varied response of 
the endogenous and newly formed ACh pools to 
muscarinic ligands relates to the well-known ACh 
compartments, namely, the synaptic vesicles and 
11 
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presynaptic cytoplasm. Most of the non-labeled 
endogenous ACh is in the bound pool [ 15,161 and 
is presumably vesicular. It is therefore tempting to 
suggest that the synaptic vesicles, in particular 
fraction VPi, which is not readily labeled with 
newly synthesized [3H]ACh [17], are the target of 
the muscarinic agonists, which presumably in- 
terfere with their mobilization from a storage pool 
to a readily available state. Since muscarinic in- 
hibition in the Torpedo seems to be mediated by 
prostaglandins [18], it will be of interest to study 
the possible involvement of prostaglandins in 
synaptic vesicle mobilization. 
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